Skip to main content

Table 1 General, clinicopathologic, treatment, and follow-up characteristics for the 715 gallbladder cancer patients with different surgery treatments

From: Impact of surgical strategies on the survival of gallbladder cancer patients: analysis of 715 cases

Variates Total Simple resection Radical resection Palliative surgery p
(n = 715) N (%) (n = 126) N (%) (n = 349) N (%) (n = 240) N (%)
Sources      0.2488
 Urban 299 (41.8) 56 (44.4) 153 (43.8) 90 (37.5)  
 Country 416 (58.2) 70 (55.6) 196 (56.2) 150 (62.5)  
Ages (years)      0.0198
 < 60 275 (38.5) 41 (32.5) 154 (44.1) 80 (33.3)  
 60–69 264 (36.9) 48 (38.1) 125 (35.8) 91 (37.9)  
 ≥ 70 176 (24.6) 37 (29.4) 70 (20.1) 69 (28.8)  
Sex      0.0573
 Female 258 (36.1) 34 (27) 130 (37.2) 94 (39.2)  
 Male 457 (63.9) 92 (73) 219 (62.8) 146 (60.8)  
BMI (Kg/m2)      0.293
 < 28 613 (85.7) 109 (86.5) 301 (86.2) 203 (84.6)  
 ≥ 28 80 (11.2) 10 (7.9) 39 (11.2) 31 (12.9)  
 Unknown 22 (3.1) 7 (5.6) 9 (2.6) 6 (2.5)  
Smoking history      0.3083
 No 568 (79.4) 105 (83.3) 279 (80) 184 (76.7)  
 Yes 147 (20.6) 21 (16.7) 70 (20) 56 (23.3)  
Gallbladder location of tumor      < 0.0001
 Fundus 208 (29.1) 45 (35.7) 123 (35.2) 40 (16.7)  
 Body 321 (44.9) 62 (49.2) 151 (43.3) 108 (45)  
 Neck 150 (21) 19 (15.1) 75 (21.5) 56 (23.3)  
 Unknown 36 (5) 0 0 36 (15)  
Clinical staging      < 0.0001
 I 35 (4.9) 20 (15.9) 15 (4.3) 0  
 II 82 (11.5) 37 (29.4) 45 (12.9) 0  
 III 291 (40.7) 59 (46.8) 214 (61.3) 18 (7.5)  
 IV 307 (42.9) 10 (7.9) 75 (21.5) 222 (92.5)  
T stage      < 0.0001
 T1 34 (4.8) 16 (12.7) 18 (5.2) 0  
 T2 92 (12.9) 38 (30.2) 53 (15.2) 1 (0.4)  
 T3 381 (53.3) 64 (50.8) 255 (73.1) 62 (25.8)  
 T4 125 (17.5) 4 (3.2) 22 (6.3) 99 (41.3)  
 Unknown 83 (11.6) 4 (3.2) 1 (0.3) 78 (32.5)  
N stage      < 0.0001
 N0 276 (38.6) 70 (55.6) 197 (56.4) 9 (3.8)  
 N1 88 (12.3) 5 (4) 77 (22.1) 6 (2.5)  
 N2 90 (12.6) 3 (2.4) 58 (16.6) 29 (12.1)  
 Unknown 211 (29.5) 48 (38.1) 17 (4.9) 146 (60.8)  
M stage      < 0.0001
 M0 524 (73.3) 119 (94.4) 338 (96.8) 67 (27.9)  
 M1 158 (22.1) 6 (4.8) 8 (2.3) 144 (60)  
 Unknown 33 (4.6) 1 (0.8) 3 (0.9) 29 (12.1)  
Grade      < 0.0001
 Well-differentiated 27 (3.8) 13 (10.3) 11 (3.2) 3 (1.3)  
 Moderately differentiated 112 (15.7) 30 (23.8) 73 (20.9) 9 (3.8)  
 Poorly differentiated 184 (25.7) 28 (22.2) 122 (35) 34 (14.2)  
 Unknown 392 (54.8) 55 (43.7) 143 (41) 194 (80.8)  
CA199      0.0266
 < 27 U/mL 262 (36.6) 59 (46.8) 168 (53.2) 35 (14.6)  
 ≥ 27 U/mL 388 (54.3) 49 (38.9) 158 (45.3) 181 (75.4)  
 Unknown 65 (9.1) 18 (14.3) 23 (6.6) 24 (10)  
CA242      
 < 20 IU/mL 296 (41.4) 61 (48.4) 171 (49) 64 (26.7) < 0.0001
 ≥ 20 IU/mL 311 (43.5) 33 (26.2) 131 (37.5) 147 (61.3)  
 Unknown 108 (15.1) 32 (25.4) 47 (23.5) 29 (12.1)  
With chronic disease      0.2935
 No 433 (60.6) 74 (58.7) 204 (58.5) 155 (64.6)  
 Yes 282 (39.4) 52 (41.3) 145 (41.5) 85 (35.4)  
 Gallstone      < 0.0001
 No 321 (44.9) 34 (27) 162 (46.4) 125 (52.1)  
 Yes 394 (55.1) 92 (73.1) 187 (53.6) 115 (47.9)  
Adjuvant therapy      < 0.0001
 None 537 (75.1) 96 (76.2) 239 (68.5) 202 (84.2)  
 Received 178 (24.9) 30 (23.8) 110 (31.5) 38 (15.8)  
Follow-up      
 Alive 212 (29.7) 59 (46.8) 136 (39) 17 (7.1)  
 3-year survival 254 (35.5) 69 (54.8) 134 (38.4) 51 (21.3)  
 Months, median(95% CI) 27 (22–31) 51 (41–69) 34 (28–44) 10 (7–14)  
  1. Results are number (%) unless otherwise specified